How India Exports Isosorbide to the World

In the United States, Isosorbide is approved for therapeutic use, with multiple Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book. Notably, Teva Pharmaceuticals received approval for Isosorbide Mononitrate Tablets under ANDA No. 75-147 on November 27, 1998. The FDA's import alert system, which facilitates Detention Without Physical Examination (DWPE) for products appearing to violate regulations, does not currently list Isosorbide or its Indian manufacturers. This absence indicates compliance with FDA standards among Indian exporters. Given that 85.6% of India's Isosorbide exports are directed to the U.S., the adherence to FDA regulations by Indian exporters is crucial for maintaining market access.

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products. Isosorbide-containing products require marketing authorization from the EMA, which involves a rigorous evaluation of quality, safety, and efficacy. Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines to ensure product quality. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicinal products, requiring marketing authorization and adherence to GMP standards. While specific EMA or MHRA actions regarding Isosorbide are not detailed in the provided data, compliance with these regulatory frameworks is essential for market entry and sustained presence in the EU and UK markets.

Isosorbide is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. This inclusion facilitates its adoption and use in various healthcare systems worldwide. Additionally, Isosorbide formulations are standardized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards ensure consistent quality and efficacy across different markets.

In India, Isosorbide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, specific ceiling prices for Isosorbide are not detailed in the provided data. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The primary patents for Isosorbide have expired, leading to a competitive market with multiple generic manufacturers. This generic competition has contributed to the widespread availability and affordability of Isosorbide in various markets.

In October 2025, the FDA updated Import Alert 66-66, which pertains to APIs that appear to be misbranded under section 502(f)(1) due to non-compliance with labeling exemptions. While Isosorbide is not specifically mentioned, this update underscores the importance of compliance with labeling requirements for all APIs.

In March 2026, the FDA issued Import Alert 99-05, concerning the detention without physical examination of raw agricultural products for pesticides. Although this alert does not directly impact Isosorbide, it highlights the FDA's ongoing efforts to ensure product safety and compliance in imported goods.

These developments reflect the dynamic nature of regulatory environments and the necessity for exporters to stay informed and compliant with evolving standards to maintain market access.

Isosorbide, a key pharmaceutical compound, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, according to the U.S. Pharmacopeia's Medicine Supply Map.

Recent disruptions have highlighted the vulnerabilities in this supply chain. For instance, in July 2024, environmental regulations led to the shutdown of several Chinese chemical plants, causing significant supply interruptions for Indian pharmaceutical manufacturers. Such events underscore the risks associated with heavy reliance on a single country for critical raw materials.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Isosorbide account for 82.2% of total exports, with TORRENT PHARMACEUTICALS LTD alone contributing 39.2%. This high supplier concentration poses a significant risk; any disruption affecting these key players could severely impact global Isosorbide supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API production and reduce import dependence. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, essential for antibiotics. While these initiatives are promising, their impact on Isosorbide production remains to be seen.

Geopolitical tensions and shipping disruptions have further complicated the Isosorbide supply chain. The Red Sea and Strait of Hormuz, critical maritime routes for Indian exports, have experienced increased instability due to regional conflicts, leading to delays and increased shipping costs. Additionally, escalating U.S.-China tensions have resulted in trade restrictions and tariffs, affecting the availability and cost of Chinese-sourced KSMs.

These disruptions have tangible effects on drug availability. For example, in February 2026, the FDA reported a shortage of Nitroglycerin, a cardiovascular medication, due to supply chain issues stemming from geopolitical conflicts and manufacturing disruptions. Such incidents highlight the broader implications of supply chain vulnerabilities in the pharmaceutical sector.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for KSMs and APIs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical raw materials and APIs to strengthen supply chain resilience.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain.

• Develop Contingency Plans: Create comprehensive strategies to address potential disruptions, including alternative shipping routes and emergency stockpiles.

• Collaborate with Regulatory Bodies: Work closely with organizations like the FDA and EMA to stay informed about regulatory changes and ensure compliance.

RISK_LEVEL: HIGH